Zealand Pharma shares gain on buyback and Roche funding

ZEALAND PHARMA A/S shares jumped 18% on Thursday morning after the company announced a $200 million share buyback and $700 million in expected milestone payments. The Denmark-based developer is leveraging these inflows to fund late-stage obesity trials without diluting current shareholders. The move addresses investor concerns about Zealand's funding for clinical development in the weight-loss sector.

### Funding the Fight Against Wegovy The expected $700 million in payments from ROCHE HOLDING AG this year eases cash runway concerns. This capital influx follows a period of volatility in March when mid-stage trial results for petrelintide disappointed some market participants. Zealand is positioning petrelintide as a once-weekly alternative to treatments from NOVO NORDISK A/S and ELI LILLY & CO.